Welcome to our dedicated page for Crescent Biopharma SEC filings (Ticker: CBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Crescent Biopharma filings document a clinical-stage oncology biotechnology issuer with ordinary shares listed on Nasdaq. The company’s Form 8-K reports furnish quarterly and annual financial results, business highlights, and pipeline updates involving CR-001, ADC programs, and collaboration activity.
Its SEC record also includes a definitive proxy statement covering governance, executive compensation, equity awards, shareholder voting matters, and board-related disclosures. Registration statement materials describe the company’s business, capitalization, preferred stock, warrants, convertible instruments, risk factors, and public-company structure.
CRESCENT BIOPHARMA, INC. officer Ryan Lynch reported an open-market sale of 465 Ordinary Shares on June 22, 2026 at a weighted average price of $17.99 per share. These shares were automatically sold to satisfy tax withholding obligations tied to the settlement of restricted stock units granted on December 15, 2025, under a pre-arranged Rule 10b5-1 instruction adopted on February 25, 2026. Following this tax-related sale, Lynch directly holds 13,871 Ordinary Shares.
CRESCENT BIOPHARMA, INC. Chief Scientific Officer Jan Pinkas reported an open-market sale of 1,288 Ordinary Shares at a weighted average price of $17.99 per share. According to the disclosure, these shares were automatically sold to cover tax withholding obligations arising from the settlement of previously granted restricted stock units.
The sale was executed under a pre-arranged Rule 10b5-1 instruction adopted on February 26, 2026, indicating it was planned in advance specifically to pay taxes on vesting rather than a discretionary portfolio decision. Following the transaction, Pinkas directly holds 22,239 Ordinary Shares.
CRESCENT BIOPHARMA, INC. Chief Financial Officer Richard William Scalzo reported an open-market sale of 1,112 ordinary shares at a weighted average price of $17.99 per share. According to the disclosure, these shares were automatically sold to satisfy tax withholding obligations tied to vested restricted stock units granted on December 15, 2025.
The sales were executed under a pre-arranged Rule 10b5-1 instruction adopted on February 25, 2026, solely to cover taxes from the RSU vesting. After this transaction, Scalzo directly holds 20,298 ordinary shares, indicating he retains a substantial equity position in the company.
CRESCENT BIOPHARMA, INC. officer Barbara Harlin Bispham reported an automatic sale of 1,218 Ordinary Shares on June 22, 2026 to cover taxes from restricted stock units vesting. The weighted average sale price was $17.99 per share, with individual trades ranging from $16.88 to $18.86. These transactions were executed under a pre-arranged Rule 10b5-1 instruction solely to satisfy tax withholding obligations. After the sale, she directly holds 19,330 Ordinary Shares.
CRESCENT BIOPHARMA, INC. Chief Medical Officer Ellie Eunkyung Im reported an open-market sale of 1,219 Ordinary Shares at a weighted average price of $17.99 per share. The footnotes explain these shares were automatically sold to satisfy tax withholding obligations tied to the vesting of restricted stock units.
The sales were executed under a pre-arranged Rule 10b5-1 instruction adopted on February 25, 2026, and were intended solely to cover taxes from the RSU settlement. After this transaction, the reporting person directly holds 22,069 Ordinary Shares.
CRESCENT BIOPHARMA, INC. President and COO Jonathan McNeill reported an open-market sale of 20,549 Ordinary Shares at a weighted average price of $17.99 per share. According to the filing, the shares were automatically sold to cover tax withholding obligations from vesting restricted stock units under a pre-arranged Rule 10b5-1 instruction. After these tax-related sales, McNeill directly holds 139,158 Ordinary Shares.
CRESCENT BIOPHARMA, INC. director and Chief Executive Officer Joshua T. Brumm reported an automatic sale of ordinary shares primarily related to equity compensation taxes. On June 22, 2026, he sold 42,305 ordinary shares at a weighted average price of $17.99 per share.
According to the disclosure, these shares were automatically sold to satisfy tax withholding obligations from the settlement of restricted stock units granted on December 15, 2025 and March 17, 2025, under a Rule 10b5-1 instruction adopted on February 28, 2026. Following the transaction, Brumm directly holds 281,212 ordinary shares of Crescent Biopharma.
Crescent Biopharma is registering for resale up to 19,580,843 ordinary shares. This prospectus supplement updates the March 3, 2026 prospectus to cover resale by selling securityholders of 19,580,843 Ordinary Shares, including specified tranches held by Fairmount Healthcare Fund II L.P.
The supplement references a Form 8-K and an amendment to the Form 10-Q, notes the Nasdaq closing price of $17.69 on June 18, 2026, and reports that 27,571,935 Ordinary Shares were outstanding as of April 24, 2026 / April 7, 2026. The resale is by selling securityholders (no proceeds to the company stated here).
Crescent Biopharma, Inc. filed Amendment No. 1 to its quarterly report for the period ended March 31, 2026 to add previously omitted disclosure about Rule 10b5-1 trading arrangements. The amendment does not change any financial statements or other disclosures from the original filing.
The company reports that on February 25, 2026 seven senior executives adopted pre-arranged “sell-to-cover” Rule 10b5-1 instructions to sell ordinary shares only as needed to cover tax withholding on vesting of restricted stock units and performance stock units granted under company equity plans. As of April 24, 2026, 27,571,935 ordinary shares were outstanding.
CRESCENT BIOPHARMA, INC. director Jonathan Violin received a grant of stock options covering 11,050 ordinary shares. The options carry an exercise price of $17.01 per share and expire on June 2, 2036. They vest in full on the earlier of June 2, 2027 or the company’s next annual shareholder meeting, subject to his continued service.